To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Hematopoietic stem-cell disorders such as sickle cell disease, thalassemias, and immunodeficiencies may be the most amenable diseases to consider for in utero treatment. Despite the theoretical advantages of in utero hematopoietic cell transplantation (IUHCTx) and its success in animal models, its efficacy in humans has been limited, and current research efforts are focused on understanding and surmounting the barriers to engraftment in the fetus. The observation that selective depletion of host hematopoietic stem cells (HSCs) prior to bone-marrow (BM) transplant results in high rates of engraftment in adult animals suggests that vacating host stem cell niches may improve chimerism after IUHCTx. Two recent studies in mice have implicated the maternal immune system in rejecting the in utero transplanted cells, and have rekindled enthusiasm in this field. Achieving donor-specific tolerance after IUHCTx has the potential to treat many hematopoietic disorders.